Onco-Innovations Limited and Redwood AI, in collaboration with Canada’s Michael Smith Genome Sciences Centre and Centre de recherche du CHU de Québec-Université Laval, have been awarded a competitive Digital Health Innovation Fund grant administered by the Terry Fox Research Institute. The grant, which is reimbursement-based, covers up to 25% of an estimated $3.5 million project budget, underscoring significant institutional support for the initiative. The project aims to develop Onco SynoGraph, an AI-driven oncology platform that leverages federated learning and causal AI to predict first-in-human clinical outcomes from preclinical studies and real-world clinico-genomic data.
This development matters because it addresses a critical bottleneck in oncology: the high failure rate of drug candidates in clinical trials. By using advanced AI to better predict how drugs will perform in humans, the platform could reduce the time and cost of bringing new cancer therapies to patients. The integration of federated learning allows multiple institutions to train models on diverse datasets without sharing sensitive patient data, preserving privacy while enhancing predictive power. Causal AI goes beyond correlation to identify true cause-and-effect relationships, which is essential for reliable clinical predictions.
Redwood AI will contribute proprietary data integration and physicochemical modelling methods, while the academic partners will provide clinico-genomic and imaging data. Onco-Innovations will contribute its causal AI methods and federated pipeline development. This synergy of industry and academia exemplifies how collaborative efforts can accelerate innovation in life sciences. For Onco-Innovations, a Canadian company focused on cancer research and treatment, this grant validates its expertise in causal AI and its potential to impact oncology. The company holds an exclusive worldwide license to patented technology for therapeutic inhibition of PNKP, a novel clinical target in DNA damage response, further strengthening its pipeline.
Investors and industry observers should note that this grant not only provides financial support but also serves as a stamp of approval from a reputable organization like the Terry Fox Research Institute. It may attract additional funding and partnerships, positioning Onco-Innovations and Redwood AI as leaders in AI-driven oncology. The project’s success could lead to more accurate predictions of drug efficacy and safety, ultimately speeding up the development of new cancer treatments and improving patient outcomes.
For more details on Onco-Innovations, visit Onco-Innovations Limited. The full press release is available at https://ibn.fm/ySIj9. Updates on ONNVF can be found at https://ibn.fm/ONNVF. The announcement was disseminated through BioMedWire, part of the Dynamic Brand Portfolio at IBN, which offers InvestorWire for wire distribution and editorial syndication to 5,000+ outlets. Their services also include press release enhancement and social media distribution, among other corporate communications solutions.
